Emerging trends in "smart probiotics": Functional consideration for the development of novel health and industrial applications

Frontiers in Microbiology

Volumn 8, Issue SEP, 2017, Pages

  El Hage, Racha ^a   Hernandez Sanabria, Emma ^a   Van de Wiele, Tom ^a  

^a GHENT UNIVERSITY   (Belgium)

Author keywords

Bacterial consortium; CDI; FMT; Next generation probiotics; Synthetic community

Indexed keywords

IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; POLYSACCHARIDE; PROBIOTIC AGENT; TOLL LIKE RECEPTOR; TRANSCRIPTION FACTOR FOXP3; VITAMIN;

AKKERMANSIA MUCINIPHILA; ANTIINFLAMMATORY ACTIVITY; BACTEROIDES FRAGILIS; BACTEROIDES UNIFORMIS; BIFIDOBACTERIUM; CLOSTRIDIUM DIFFICILE INFECTION; COLITIS; COLLINSELLA AEROFACIENS; DYSBIOSIS; EUBACTERIUM; FAECALIBACTERIUM; FAECALIBACTERIUM PRAUSNITZII; FECAL MICROBIOTA TRANSPLANTATION; HEALTH; HUMAN; IMMUNE SYSTEM; INDUSTRY; INFLAMMATORY BOWEL DISEASE; INTESTINE FLORA; LACTIC ACID BACTERIUM; LACTOBACILLUS; MEDICINAL SPECIES; METABOLIC BALANCE; MICROBIAL COMMUNITY; NONHUMAN; PARABACTEROIDES; PEPTOCLOSTRIDIUM DIFFICILE; PREGNANCY DIABETES MELLITUS; RAOULTELLA; REGULATORY T LYMPHOCYTE; REVIEW; RUMINOCOCCUS; VERRUCOMICROBIA;

EID: 85030150098     PISSN: None     EISSN: 1664302X     Source Type: Journal    
DOI: 10.3389/fmicb.2017.01889     Document Type: Review

References (130)

1. Asemi, Z., Zare, Z., Shakeri, H., Sabihi, S.-S., and Esmaillzadeh, A. (2013). Effect of multispecies probiotic supplements on metabolic profiles, Hs-CRP, and oxidative stress in patients with Type 2 diabetes. Ann. Nutr. Metab. 63, 1-9. doi: 10.1159/000349922
2. Atarashi, K., Tanoue, T., Oshima, K., Suda, W., Nagano, Y., Nishikawa, H., et al. (2013). Treg induction by a rationally selected mixture of Clostridia strains from the human microbiota. Nature 500, 232-236. doi: 10.1038/nature12331
3. Atarashi, K., Tanoue, T., Shima, T., Imaoka, A., Kuwahara, T., Momose, Y., et al. (2011). Induction of colonic regulatory T cells by indigenous Clostridium species. Science 331, 337-341. doi: 10.1126/science.1198469
4. Bakken, J. S. (2009). Fecal bacteriotherapy for recurrent Clostridium difficile infection. Anaerobe 15, 285-289. doi: 10.1016/j.anaerobe.2009.09.007
5. Bakken, J. S., Borody, T., Brandt, L. J., Brill, J. V., Demarco, D. C., Franzos, M. A., et al. (2011). Treating Clostridium difficile infection with fecal microbiota transplantation. Clin. Gastroenterol. Hepatol. 9, 1044-1049. doi: 10.1016/j.cgh.2011.08.014
6. Baldi, A., and Arora, M. (2015). Regulatory categories of probiotics across the globe: a review representing existing and recommended categorization. Indian J. Med. Microbiol. 33(Suppl.), 2-10. doi: 10.4103/0255-0857.150868
7. Barbut, F., Richard, A., Hamadi, K., Chomette, V., Burghoffer, B., and Petit, J.-C. (2000). Epidemiology of recurrences or reinfections of Clostridium difficile-associated diarrhea. J. Clin. Microbiol. 38, 2386-2388.
8. Bartlett, J. G. (1990). Clostridium difficile: clinical considerations. Clin. Infect. Dis. 12(Suppl. 2), S243-S251. doi: 10.1093/clinids/12.supplement_2.s243
9. Becattini, S., Taur, Y., and Pamer, E. G. (2016). Antibiotic-induced changes in the intestinal microbiota and disease. Trends Mol. Med. 22, 458-478. doi: 10.1016/j.molmed.2016.04.003
10. Besseling-van der Vaart, I., Heath, M. D., Guagnini, F., and Kramer, M. F. (2016). In vitro evidence for efficacy in food intolerance for the multispecies probiotic formulation Ecologic® Tolerance (SyngutTM). Benef. Microbes 7, 111-118. doi: 10.3920/bm2015.0051
11. Brandt, L. J. (2012). Fecal transplantation for the treatment of Clostridium difficile infection. Gastroenterol. Hepatol. 8, 191-194.
12. Breyner, N. M., Michon, C., de Sousa, C. S., Vilas Boas, P. B., Chain, F., Azevedo, V. A., et al. (2017). Microbial anti-inflammatory molecule (MAM) from Faecalibacterium prausnitzii shows a protective effect on DNBS and DSS-induced colitis model in mice through inhibition of NF-κB pathway. Front. Microbiol. 8:114. doi: 10.3389/fmicb.2017.00114
13. Cani, P. D., and Van Hul, M. (2015). Novel opportunities for next-generation probiotics targeting metabolic syndrome. Curr. Opin. Biotechnol. 32, 21-27. doi: 10.1016/j.copbio.2014.10.006
14. Chapman, C., Gibson, G., and Rowland, I. (2011). Health benefits of probiotics: are mixtures more effective than single strains? Eur. J. Nutr. 50, 1-17. doi: 10.1007/s00394-010-0166-z
15. Chen, J., Wang, R., Li, X.-F., and Wang, R.-L. (2011). Bifidobacterium adolescentis supplementation ameliorates visceral fat accumulation and insulin sensitivity in an experimental model of the metabolic syndrome. Br. J. Nutr. 107, 1429-1434. doi: 10.1017/s0007114511004491
16. Clarke, S. F., Murphy, E. F., O'Sullivan, O., Lucey, A. J., Humphreys, M., Hogan, A., et al. (2014). Exercise and associated dietary extremes impact on gut microbial diversity. Gut 63, 1913-1920. doi: 10.1136/gutjnl-2013-306541
17. Damin, M. R., Minowa, E., Alcântara, M. R., and Oliveira, M. N. (2008). Effect of cold storage on culture viability and some rheological properties of fermented milk prepared with yogurt and probiotic bacteria. J. Texture Stud. 39, 40-55. doi: 10.1111/j.1745-4603.2007.00129.x
18. Dao, M. C., Everard, A., Aron-Wisnewsky, J., Sokolovska, N., Prifti, E., Verger, E. O., et al. (2016). Akkermansia muciniphila and improved metabolic health during a dietary intervention in obesity: relationship with gut microbiome richness and ecology. Gut 65, 426-436. doi: 10.1136/gutjnl-2014-308778
19. De Palma, G., Collins, S. M., and Bercik, P. (2014). The microbiota-gut-brain axis in functional gastrointestinal disorders. Gut Microbes 5, 419-429. doi: 10.4161/gmic.29417
20. De Palma, G., Lynch, M. D. J., Lu, J., Dang, V. T., Deng, Y., Jury, J., et al. (2017). Transplantation of fecal microbiota from patients with irritable bowel syndrome alters gut function and behavior in recipient mice. Sci. Transl. Med. 9:eaaf6397. doi: 10.1126/scitranslmed.aaf6397
21. den Besten, G., van Eunen, K., Groen, A. K., Venema, K., Reijngoud, D.-J., and Bakker, B. M. (2013). The role of short-chain fatty acids in the interplay between diet, gut microbiota, and host energy metabolism. J. Lipid Res. 54, 2325-2340. doi: 10.1194/jlr.r036012
22. Dethlefsen, L., and Relman, D. A. (2010). Incomplete recovery and individualized responses of the human distal gut microbiota to repeated antibiotic perturbation. Proc. Natl. Acad. Sci. U.S.A. 108(Suppl. 1), 4554-4561. doi: 10.1073/pnas.1000087107
23. Di Cerbo, A., Palmieri, B., Aponte, M., Morales-Medina, J. C., and Iannitti, T. (2016). Mechanisms and therapeutic effectiveness of lactobacilli. J. Clin. Pathol. 69, 187-203. doi: 10.1136/jclinpath-2015-202976
24. Distrutti, E., Monaldi, L., Ricci, P., and Fiorucci, S. (2016). Gut microbiota role in irritable bowel syndrome: new therapeutic strategies. World J. Gastroenterol. 22, 2219-2241. doi: 10.3748/wjg.v22.i7.2219
25. EFSA Panel on Biological Hazards (BIOHAZ) (2013). Scientific opinion on the maintenance of the list of QPS biological agents intentionally added to food and feed (2013 update). EFSA J. 11:3449. doi: 10.2903/j.efsa.2013.3449
26. Engels, C., Ruscheweyh, H.-J., Beerenwinkel, N., Lacroix, C., and Schwab, C. (2016). The common gut microbe Eubacterium hallii also contributes to intestinal propionate formation. Front. Microbiol. 7:713. doi: 10.3389/fmicb.2016.00713
27. Evans, C. T., and Johnson, S. (2015). Prevention of Clostridium difficile infection with probiotics. Clin. Infect. Dis. 60(Suppl. 2), S122-S128. doi: 10.1093/cid/civ138
28. Everard, A., Lazarevic, V., Gaïa, N., Johansson, M., Ståhlman, M., Backhed, F., et al. (2014). Microbiome of prebiotic-treated mice reveals novel targets involved in host response during obesity. ISME J. 8, 2116-2130. doi: 10.1038/ismej.2014.45
29. Fernández-Murga, M. L., and Sanz, Y. (2016). Safety assessment of Bacteroides uniformis CECT 7771 isolated from stools of healthy breast-fed infants. PLOS ONE 11:e0145503. doi: 10.1371/journal.pone.0145503
30. Figueroa, I., Johnson, S., Sambol, S. P., Goldstein, E. J. C., Citron, D. M., and Gerding, D. N. (2012). Relapse versus reinfection: recurrent Clostridium difficile infection following treatment with fidaxomicin or vancomycin. Clin. Infect. Dis. 55(Suppl. 2), S104-S109. doi: 10.1093/cid/cis357
31. Francino, M. P. (2016). Antibiotics and the human gut microbiome: dysbioses and accumulation of resistances. Front. Microbiol. 6:1543. doi: 10.3389/fmicb.2015.01543
32. Gauffin Cano, P., Santacruz, A., Moya, á., and Sanz, Y. (2012). Bacteroides uniformis CECT 7771 ameliorates metabolic and immunological dysfunction in mice with high-fat-diet induced obesity. PLOS ONE 7:e41079. doi: 10.1371/journal.pone.0041079
33. Gibson, G. R., Hutkins, R., Sanders, M. E., Prescott, S. L., Reimer, R. A., Salminen, S. J., et al. (2017). Expert consensus document: the international scientific association for probiotics and prebiotics (ISAPP) consensus statement on the definition and scope of prebiotics. Nat. Rev. Gastroenterol. Hepatol. 14, 491-502. doi: 10.1038/nrgastro.2017.75
34. Goldenberg, J. Z., Ma, S. S. Y., Saxton, J. D., Martzen, M. R., Vandvik, P. O., Thorlund, K., et al. (2013). Probiotics for the prevention of Clostridium difficile-associated diarrhea in adults and children. Cochrane Database Syst. Rev. doi: 10.1002/14651858.CD006095.pub3
35. Govender, M., Choonara, Y. E., Kumar, P., du Toit, L. C., van Vuuren, S., and Pillay, V. (2013). A review of the advancements in probiotic delivery: conventional vs. non-conventional formulations for intestinal flora supplementation. AAPS PharmsciTech 15, 29-43. doi: 10.1208/s12249-013-0027-1
36. Graf, D., Di Cagno, R., Fåk, F., Flint, H. J., Nyman, M., Saarela, M., et al. (2015). Contribution Of diet to the composition of the human gut microbiota. Microb. Ecol. Health Dis. 26:26164. doi: 10.3402/mehd.v26.26164
37. Guarner, F., and Malagelada, J.-R. (2003). Gut flora in health and disease. Lancet 361, 512-519. doi: 10.1016/s0140-6736(03)12489-0
38. Gueimonde, M., and Sánchez, B. (2012). Enhancing probiotic stability in industrial processes. Microb. Ecol. Health Dis. 23:18562. doi: 10.3402/mehd.v23i0.18562
39. Hand, T. W. (2016). The role of the microbiota in shaping infectious immunity. Trends Immunol. 37, 647-658. doi: 10.1016/j.it.2016.08.007
40. Hartstra, A. V., Bouter, K. E. C., Bäckhed, F., and Nieuwdorp, M. (2015). Insights into the role of the microbiome in obesity and type 2 diabetes. Diabetes Care 38, 159-165. doi: 10.2337/dc14-0769
41. Heidebach, T., Först, P., and Kulozik, U. (2012). Microencapsulation of probiotic cells for food applications. Crit. Rev. Food Sci. Nutr. 52, 291-311. doi: 10.1080/10408398.2010.499801
42. Hill, C., Guarner, F., Reid, G., Gibson, G. R., Merenstein, D. J., Pot, B., et al. (2014). Expert consensus document: the international scientific association for probiotics and prebiotics consensus statement on the scope and appropriate use of the term probiotic. Nat. Rev. Gastroenterol. Hepatol. 11, 506-514. doi: 10.1038/nrgastro.2014.66
43. Jafarnejad, S., Saremi, S., Jafarnejad, F., and Arab, A. (2016). Effects of a multispecies probiotic mixture on glycemic control and inflammatory status in women with gestational diabetes: a randomized controlled clinical trial. J. Nutr. Metab. 2016:5190846. doi: 10.1155/2016/5190846
44. Jiang, Z.-D., Hoang, L. N., Lasco, T. M., Garey, K. W., and DuPont, H. L. (2013). Physician attitudes toward the use of fecal transplantation for recurrent Clostridium difficile infection in a metropolitan area. Clin. Infect. Dis. 56, 1059-1060. doi: 10.1093/cid/cis1025
45. Johnson, S., Adelmann, A., Clabots, C. R., Peterson, L. R., and Gerding, D. N. (1989). Recurrences of Clostridium difficile diarrhea not caused by the original infecting organism. J. Infect. Dis. 159, 340-343. doi: 10.1093/infdis/159.2.340
46. Kasinska, M. A., and Drzewoski, J. (2015). Effectiveness of probiotics in Type 2 diabetes: a meta-analysis. Pol. Arch. Intern. Med. 125, 803-813. doi: 10.20452/pamw.3156
47. Kelly, C. P. (2009). A 76-year-old man with recurrent Clostridium difficile-associated diarrhea. JAMA 301, 954-962. doi: 10.1001/jama.2009.171
48. Kelly, C. P. (2013). Fecal microbiota transplantation-an old therapy comes of age. N. Engl. J. Med. 368, 474-475. doi: 10.1056/nejme1214816
49. Khanna, S., Pardi, D. S., Kelly, C. R., Kraft, C. S., Dhere, T., Henn, M. R., et al. (2016). A novel microbiome therapeutic increases gut microbial diversity and prevents recurrent Clostridium difficile infection. J. Infect. Dis. 214, 173-181. doi: 10.1093/infdis/jiv766
50. Kim, S.-W., Park, K.-Y., Kim, B., Kim, E., and Hyun, C.-K. (2013). Lactobacillus rhamnosus GG improves insulin sensitivity and reduces adiposity in high-fat diet-fed mice through enhancement of adiponectin production. Biochem. Biophys. Res. Commun. 431, 258-263. doi: 10.1016/j.bbrc.2012.12.121
51. Klaenhammer, T. R., Kleerebezem, M., Kopp, M. V., and Rescigno, M. (2012). The impact of probiotics and prebiotics on the immune system. Nat. Rev. Immunol. 12, 728-734. doi: 10.1038/nri3312
52. Kobyliak, N., Conte, C., Cammarota, G., Haley, A. P., Styriak, I., Gaspar, L., et al. (2016). Probiotics in prevention and treatment of obesity: a critical view. Nutr. Metab. 13, 14. doi: 10.1186/s12986-016-0067-0
53. Koning, C. J., Jonkers, D. M., Stobberingh, E. E., Mulder, L., Rombouts, F. M., and Stockbrügger, R. W. (2008). The effect of a multispecies probiotic on the intestinal microbiota and bowel movements in healthy volunteers taking the antibiotic amoxycillin. Am. J. Gastroenterol. 103, 178-189. doi: 10.1111/j.1572-0241.2007.01547.x
54. Kristensen, N. B., Bryrup, T., Allin, K. H., Nielsen, T., Hansen, T. H., and Pedersen, O. (2016). Alterations in fecal microbiota composition by probiotic supplementation in healthy adults: a systematic review of randomized controlled trials. Genome Med. 8, 52. doi: 10.1186/s13073-016-0300-5
55. Kwon, H.-K., Lee, C.-G., So, J.-S., Chae, C.-S., Hwang, J.-S., Sahoo, A., et al. (2010). Generation of regulatory dendritic cells and CD4+Foxp3+ T cells by probiotics administration suppresses immune disorders. Proc. Natl. Acad. Sci. U.S.A. 107, 2159-2164. doi: 10.1073/pnas.0904055107
56. Langdon, A., Crook, N., and Dantas, G. (2016). The effects of antibiotics on the microbiome throughout development and alternative approaches for therapeutic modulation. Genome Med. 8:39. doi: 10.1186/s13073-016-0294-z
57. Leszczyszyn, J. J., Radomski, M., and Leszczyszyn, A. M. (2016). Intestinal microbiota transplant-current state of knowledge. Reumatologia 54, 24-28. doi: 10.5114/reum.2016.58758
58. Li, J., Lin, S., Vanhoutte, P. M., Woo, C. W., and Xu, A. (2016). Akkermansia muciniphila protects against atherosclerosis by preventing metabolic endotoxemia-induced inflammation in apoe-/-mice clinical. Circulation 133, 2434-2446. doi: 10.1161/circulationaha.115.019645
59. Lowes, R. (2016). FDA Proposes Tighter Rules For Fecal Transplants. New York, NY: Medscape.
60. Macpherson, A. J., de Agüero, M. G., and Ganal-Vonarburg, S. C. (2017). How nutrition and the maternal microbiota shape the neonatal immune system. Nat. Rev. Immunol. 17, 508-517. doi: 10.1038/nri.2017.58
61. Marotz, C. A., and Zarrinpar, A. (2016). Treating obesity and metabolic syndrome with fecal microbiota transplantation. Yale J. Biol. Med. 89, 383-388.
62. Marsh, J. W., Arora, R., Schlackman, J. L., Shutt, K. A., Curry, S. R., and Harrison, L. H. (2012). Association of relapse of Clostridium difficile disease with BI/NAP1/027. J. Clin. Microbiol. 50, 4078-4082. doi: 10.1128/jcm.02291-12
63. Martín, R., Chain, F., Miquel, S., Lu, J., Gratadoux, J.-J., Sokol, H., et al. (2014). The commensal bacterium Faecalibacterium prausnitzii is protective in DNBS-induced chronic moderate and severe colitis models. Inflamm. Bowel Dis. 20, 417-430. doi: 10.1097/01.mib.0000440815.76627.64
64. Martín, R., Miquel, S., Benevides, L., Bridonneau, C., Robert, V., Hudault, S., et al. (2017). Functional characterization of novel Faecalibacterium prausnitzii strains isolated from healthy volunteers: a step forward in the use of F. prausnitzii as a next-generation probiotic. Front. Microbiol. 8:1226. doi: 10.3389/fmicb.2017.01226
65. Miettinen, M., Vuopio-Varkila, J., and Varkila, K. (1996). Production of human tumor necrosis factor alpha, interleukin-6, and interleukin-10 is induced by lactic acid bacteria. Infect. Immun. 64, 5403-5405.
66. Miquel, S., Leclerc, M., Martin, R., Chain, F., Lenoir, M., Raguideau, S., et al. (2015). Identification of metabolic signatures linked to anti-inflammatory effects of Faecalibacterium prausnitzii. mBio 6:e00300-15. doi: 10.1128/mbio.00300-15
67. Moayyedi, P., Surette, M. G., Kim, P. T., Libertucci, J., Wolfe, M., Onischi, C., et al. (2015). Fecal microbiota transplantation induces remission in patients with active ulcerative colitis in a randomized controlled trial. Gastroenterology 149, 102.e6-109.e6. doi: 10.1053/j.gastro.2015.04.001
68. Nazemian, V., Shadnoush, M., Manaheji, H., and Zaringhalam, J. (2016). Probiotics and inflammatory pain: a literature review study. Middle East J. Rehabil. Health Stud. 3:e36087. doi: 10.17795/mejrh-36087
69. Neef, A., and Sanz, Y. (2013). Future for probiotic science in functional food and dietary supplement development. Curr. Opin. Clin. Nutr. Metab. Care 16, 679-687. doi: 10.1097/mco.0b013e328365c258
70. Ng, S. C., Hart, A. L., Kamm, M. A., Stagg, A. J., and Knight, S. C. (2009). Mechanisms of action of probiotics: recent advances. Inflamm. Bowel Dis. 15, 300-310. doi: 10.1002/ibd.20602
71. Orenstein, R., Dubberke, E., Hardi, R., Ray, A., Mullane, K., Pardi, D. S., et al. (2015). Safety and durability of RBX2660 (microbiota suspension) for recurrent Clostridium difficile infection: results of the PUNCH CD study. Clin. Infect. Dis. 62, 596-602. doi: 10.1093/cid/civ938
72. Patel, R., and DuPont, H. L. (2015). New approaches for bacteriotherapy: prebiotics, new-generation probiotics, and synbiotics. Clin. Infect. Dis. 60(Suppl. 2), S108-S121. doi: 10.1093/cid/civ177
73. Patrascu, O., Béguet-Crespel, F., Marinelli, L., Le Chatelier, E., Abraham, A. L., Leclerc, M., et al. (2017). A fibrolytic potential in the human ileum mucosal microbiota revealed by functional metagenomic. Sci. Rep. 7:40248. doi: 10.1038/srep40248
74. Pattani, R., Palda, V. A., Hwang, S. W., and Shah, P. S. (2013). Probiotics for the prevention of antibiotic-associated diarrhea and Clostridium difficile infection among hospitalized patients: systematic review and meta-analysis. Open Med. 7, 56-67.
75. Paulo Sousa e Silva, J., and Freitas, A. C. (2014). Probiotic Bacteria, 1st Edn. Singapore: Pan Stanford Publishing.
76. Pérez-Cobas, A., Moya, A., Gosalbes, M., and Latorre, A. (2015). Colonization resistance of the gut microbiota against Clostridium difficile. Antibiotics 4, 337-357. doi: 10.3390/antibiotics4030337
77. Petrof, E. O., Gloor, G. B., Vanner, S. J., Weese, S. J., Carter, D., Daigneault, M. C., et al. (2013). Stool substitute transplant therapy for the eradication of Clostridium difficile infection: 'RePOOPulating' the gut. Microbiome 1:3. doi: 10.1186/2049-2618-1-3
78. Pharmabiotic Research Institute (2017). PRI: Microbiotic Medicinal Products. Available at: http://www.pharmabiotic.org/
79. Pigneur, B., and Sokol, H. (2016). Fecal microbiota transplantation in inflammatory bowel disease: the quest for the holy grail. Mucosal Immunol. 9, 1360-1365. doi: 10.1038/mi.2016.67
80. Pinto-Sanchez, M. I., Hall, G. B., Ghajar, K., Nardelli, A., Bolino, C., Lau, J. T., et al. (2017). Probiotic Bifidobacterium longum NCC3001 reduces depression scores and alters brain activity: a pilot study in patients with irritable bowel syndrome. Gastroenterology 153, 448.e8-459.e8. doi: 10.1053/j.gastro.2017.05.003
81. Plaza-Diaz, J. (2014). Modulation of immunity and inflammatory gene expression in the gut, in inflammatory diseases of the gut and in the liver by probiotics. World J. Gastroenterol. 20:15632. doi: 10.3748/wjg.v20.i42.15632
82. Plaza-Diaz, J., Gomez-Llorente, C., Abadia-Molina, F., Saez-Lara, M. J., Campaña-Martin, L., Muñoz-Quezada, S., et al. (2014). Effects of Lactobacillus paracasei CNCM I-4034, Bifidobacterium breve CNCM I-4035 and Lactobacillus rhamnosus CNCM I-4036 on hepatic steatosis in zucker rats. PLOS ONE 9:e98401. doi: 10.1371/journal.pone.0098401
83. Quévrain, E., Maubert, M. A., Michon, C., Chain, F., Marquant, R., Tailhades, J., et al. (2016). Identification of an anti-inflammatory protein from Faecalibacterium prausnitzii, a commensal bacterium deficient in Crohn's disease. Gut 65, 415-425. doi: 10.1136/gutjnl-2014-307649
84. Ramesh, M., Khanna, S., Messer, J., and Adams, M. (2016). Prevention of Recurrent C. difficile Infection with RBX2660 | PUNCH CD 2 Results. Roseville, MN: Rebiotix.
85. Rao, K., and Safdar, N. (2015). Fecal microbiota transplantation for the treatment of Clostridium difficile infection. J. Hosp. Med. 11, 56-61. doi: 10.1002/jhm.2449
86. Rao, K., and Young, V. B. (2017). Probiotics for prevention of Clostridium difficile infection in hospitalized patients: is the jury still out? Gastroenterology 152, 1817-1819. doi: 10.1053/j.gastro.2017.04.027
87. Ratner, M. (2015). Microbial cocktails join fecal transplants in IBD treatment trials. Nat. Biotechnol. 33, 787-788. doi: 10.1038/nbt0815-787
88. Reardon, S. (2014). Microbiome therapy gains market traction. Nature 509, 269-270. doi: 10.1038/509269a
89. Rebiotix Media (2015). Rebiotix Receives Breakthrough Therapy Designation for RBX2660-A Microbiota Restoration Therapy (MRT) for the Treatment of Recurrent Clostridium difficile Infection. Available at: http://www.rebiotix.com/wp-content/uploads/rebiotix_receives_breakthrough_therapy_designation_recurrent_clostridium_difficile.pdf
90. Reichold, A., Brenner, S. A., Spruss, A., Förster-Fromme, K., Bergheim, I., and Bischoff, S. C. (2014). Bifidobacterium adolescentis protects from the development of nonalcoholic steatohepatitis in a mouse model. J. Nutr. Biochem. 25, 118-125. doi: 10.1016/j.jnutbio.2013.09.011
91. Reijnders, D., Goossens, G. H., Hermes, G. D., Neis, E. P., van der Beek, C. M., Most, J., et al. (2016). Effects of gut microbiota manipulation by antibiotics on host metabolism in obese humans: a randomized double-blind placebo-controlled trial. Cell Metab. 24, 63-74. doi: 10.1016/j.cmet.2016.07.008
92. Ricci, A., Allende, A., Bolton, D., Chemaly, M., Davies, R., Girones, R., et al. (2017). Update of the list of QPS-recommended biological agents intentionally added to food or feed as notified to EFSA 5: suitability of taxonomic units notified to EFSA until September 2016. EFSA J. 15:4663. doi: 10.2903/j.efsa.2017.4663
93. Rivière, A., Selak, M., Lantin, D., Leroy, F., and De Vuyst, L. (2016). Bifidobacteria and butyrate-producing colon bacteria: importance and strategies for their stimulation in the human gut. Front. Microbiol. 7:979. doi: 10.3389/fmicb.2016.00979
94. Round, J. L., Lee, S. M., Li, J., Tran, G., Jabri, B., Chatila, T. A., et al. (2011). The toll-like receptor 2 pathway establishes colonization by a commensal of the human microbiota. Science 332, 974-977. doi: 10.1126/science.1206095
95. Round, J. L., and Mazmanian, S. K. (2009). The gut microbiota shapes intestinal immune responses during health and disease. Nat. Rev. Immunol. 9, 600-600. doi: 10.1038/nri2614
96. Sanders, M. E. (2008). Probiotics: definition, sources, selection, and uses. Clin. Infect. Dis. 46, S58-S61. doi: 10.1086/523341
97. Sang, L.-X. (2010). Remission induction and maintenance effect of probiotics on ulcerative colitis: a meta-analysis. World J. Gastroenterol. 16:1908. doi: 10.3748/wjg.v16.i15.1908
98. Saulnier, D. M., Ringel, Y., Heyman, M. B., Foster, J. A., Bercik, P., Shulman, R. J., et al. (2013). The intestinal microbiome, probiotics and prebiotics in neurogastroenterology. Gut Microbes 4, 17-27. doi: 10.4161/gmic.22973
99. Savcheniuk, O., Kobyliak, N., Kondro, M., Virchenko, O., Falalyeyeva, T., and Beregova, T. (2014). Short-term periodic consumption of multiprobiotic from childhood improves insulin sensitivity, prevents development of non-alcoholic fatty liver disease and adiposity in adult rats with glutamate-induced obesity. BMC Complement. Altern. Med. 14:247. doi: 10.1186/1472-6882-14-247
100. Sbahi, H., and Di Palma, J. A. (2016). Faecal microbiota transplantation: applications and limitations in treating gastrointestinal disorders. BMJ Open Gastroenterol. 3:e000087. doi: 10.1136/bmjgast-2016-000087
101. Schneeberger, M., Everard, A., Gómez-Valadés, A. G., Matamoros, S., Ramírez, S., Delzenne, N. M., et al. (2015). Akkermansia muciniphila inversely correlates with the onset of inflammation, altered adipose tissue metabolism and metabolic disorders during obesity in mice. Sci. Rep. 5:16643. doi: 10.1038/srep16643
102. Scott, K. P., Antoine, J. M., Midtvedt, T., and van Hemert, S. (2015). Manipulating the gut microbiota to maintain health and treat disease. Microb. Ecol. Health Dis. 26:25877. doi: 10.3402/mehd.v26.25877
103. Seres Therapeutics (2015). Seres Therapeutics, Inc. Announces FDA Orphan Drug Designation for SER-109 for the Prevention of Recurrent Clostridium difficile Infection in Adults. Available at: http://ir.serestherapeutics.com/phoenix.zhtml?c=254006&p=irol-newsArticle&ID=2081167
104. Seres Therapeutics (2017). Inflammatory Bowel Disease. Serestherapeutics. Com. Available at: http://www.serestherapeutics.com/pipeline/products/inflammatory-bowel-disease
105. Shah, N. P., Ding, W. K., Fallourd, M. J., and Leyer, G. (2010). Improving the stability of probiotic bacteria in model fruit juices using vitamins and antioxidants. J. Food Sci. 75, M278-M282. doi: 10.1111/j.1750-3841.2010.01628.x
106. Shi, Y., Dong, Y., Huang, W., Zhu, D., Mao, H., and Su, P. (2016). Fecal microbiota transplantation for ulcerative colitis: a systematic review and meta-analysis. PLOS ONE 11:e0157259. doi: 10.1371/journal.pone.0157259
107. Sokol, H., Galperine, T., Kapel, N., Bourlioux, P., Seksik, P., Barbut, F., et al. (2016). Faecal microbiota transplantation in recurrent Clostridium difficile infection: recommendations from the French group of faecal microbiota transplantation. Dig. Liver Dis. 48, 242-247. doi: 10.1016/j.dld.2015.08.017
108. Sokol, H., Pigneur, B., Watterlot, L., Lakhdari, O., Bermudez-Humaran, L. G., Gratadoux, J.-J., et al. (2008). Faecalibacterium prausnitzii is an anti-inflammatory commensal bacterium identified by gut microbiota analysis of Crohn disease patients. Proc. Natl. Acad. Sci. U.S.A. 105, 16731-16736. doi: 10.1073/pnas.0804812105
109. Steenbergen, L., Sellaro, R., van Hemert, S., Bosch, J. A., and Colzato, L. S. (2015). A randomized controlled trial to test the effect of multispecies probiotics on cognitive reactivity to sad mood. Brain Behav. Immun. 48, 258-264. doi: 10.1016/j.bbi.2015.04.003
110. Surawicz, C. M., Brandt, L. J., Binion, D. G., Ananthakrishnan, A. N., Curry, S. R., Gilligan, P. H., et al. (2013). Guidelines for diagnosis, treatment, and prevention of Clostridium difficile infections. Am. J. Gastroenterol. 108, 478-498. doi: 10.1038/ajg.2013.4
111. Timmerman, H. M., Koning, C. J. M., Mulder, L., Rombouts, F. M., and Beynen, A. C. (2004). Monostrain, multistrain and multispecies probiotics-a comparison of functionality and efficacy. Int. J. Food Microbiol. 96, 219-233. doi: 10.1016/j.ijfoodmicro.2004.05.012
112. Timmerman, H. M., Niers, L. E. M., Ridwan, B. U., Koning, C. J. M., Mulder, L., Akkermans, L. M. A., et al. (2007). Design of a multispecies probiotic mixture to prevent infectious complications in critically ill patients. Clin. Nutr. 26, 450-459. doi: 10.1016/j.clnu.2007.04.008
113. Troy, E. B., and Kasper, D. L. (2010). Beneficial effects of Bacteroides fragilis polysaccharides on the immune system. Front. Biosci. 15, 25-34. doi: 10.2741/3603
114. Udayappan, S., Manneras-Holm, L., Chaplin-Scott, A., Belzer, C., Herrema, H., Dallinga-Thie, G.-M., et al. (2016). Oral treatment with Eubacterium hallii improves insulin sensitivity in db/db mice. NPJ Biofilms Microbiomes 2:16009. doi: 10.1038/npjbiofilms.2016.9
115. van der Lelie, D., Taghavi, S., Henry, C., and Gilbert, J. A. (2017). The microbiome as a source of new enterprises and job creation: considering clinical faecal and synthetic microbiome transplants and therapeutic regulation. Microb. Biotechnol. 10, 4-5. doi: 10.1111/1751-7915.12597
116. van Minnen, L. P., Timmerman, H. M., Lutgendorff, F., Verheem, A., Harmsen, W., Konstantinov, S. R., et al. (2007). Modification of intestinal flora with multispecies probiotics reduces bacterial translocation and improves clinical course in a rat model of acute pancreatitis. Surgery 141, 470-480. doi: 10.1016/j.surg.2006.10.007
117. van Nood, E., Speelman, P., Nieuwdorp, M., and Keller, J. (2014). Fecal Microbiota Transplantation. New York, NY: Medscape.
118. Venturi, A., Gionchetti, P., Rizzello, F., Johansson, R., Zucconi, E., Brigidi, P., et al. (1999). Impact on the composition of the faecal flora by a new probiotic preparation: preliminary data on maintenance treatment of patients with ulcerative colitis. Aliment. Pharmacol. Ther. 13, 1103-1108. doi: 10.1046/j.1365-2036.1999.00560.x
119. Vermeire, S., Joossens, M., Verbeke, K., Wang, J., Machiels, K., Sabino, J., et al. (2015). Donor species richness determines faecal microbiota transplantation success in inflammatory bowel disease. J. Crohns Colitis 10, 387-394. doi: 10.1093/ecco-jcc/jjv203
120. Wallace, C. J. K., and Milev, R. (2017). The effects of probiotics on depressive symptoms in humans: a systematic review. Ann. Gen. Psychiatry 16, 14. doi: 10.1186/s12991-017-0141-7
121. Wang, J., Tang, H., Zhang, C., Zhao, Y., Derrien, M., Rocher, E., et al. (2014). Modulation of gut microbiota during probiotic-mediated attenuation of metabolic syndrome in high fat diet-fed mice. ISME J. 9, 1-15. doi: 10.1038/ismej.2014.99
122. Wexler, H. M. (2007). Bacteroides: the good, the bad, and the nitty-gritty. Clin. Microbiol. Rev. 20, 593-621. doi: 10.1128/cmr.00008-07
123. WHO/FAO (2006). Probiotics in Food Health and Nutritional Properties and Guidelines for Evaluation. Rome: Food and Agriculture Organization of the United Nations.
124. Yan, F., and Polk, D. B. (2011). Probiotics and immune health. Curr. Opin. Gastroenterol. 27, 496-501. doi: 10.1097/mog.0b013e32834baa4d
125. Yang, J.-Y., Lee, Y.-S., Kim, Y., Lee, S.-H., Ryu, S., Fukuda, S., et al. (2016). Gut Commensal Bacteroides acidifaciens prevents obesity and improves insulin sensitivity in mice. Mucosal Immunol. 10, 104-116. doi: 10.1038/mi.2016.42
126. Yin, Y.-N. (2010). Effects of four Bifidobacteria on obesity in high-fat diet induced rats. World J. Gastroenterol. 16:3394. doi: 10.3748/wjg.v16.i27.3394
127. Yoon, J. S., Sohn, W., Lee, O. Y., Lee, S. P., Lee, K. N., Jun, D. W., et al. (2013). Effect of multispecies probiotics on irritable bowel syndrome: a randomized, double-blind, placebo-controlled trial. J. Gastroenterol. Hepatol. 29, 52-59. doi: 10.1111/jgh.12322
128. Youngster, I., Russell, G., Pindar, C., Sauk, J., and Hohmann, E. (2014). 1798Oral, frozen fecal microbiota capsules for relapsing Clostridium difficile infection. Open Forum Infect. Dis. 1(Suppl. 1), S62-S62. doi: 10.1093/ofid/ofu051.170
129. Zhou, D. (2016). Impact of sanitary living environment on gut microbiota. Precis. Med. 2:e1161. doi: 10.14800/pm.1161
130. Zipursky, J. S., Sidorsky, T. I., Freedman, C. A., Sidorsky, M. N., and Kirkland, K. B. (2014). Patient attitudes toward the use of fecal microbiota transplantation in the treatment of recurrent Clostridium difficile infection. Clin. Infect. Dis. 55, 1652-1658. doi: 10.1093/cid/cis809